Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Ginkgo Bioworks Holdings
DNA
DNA
Ginkgo Bioworks Holdings
Automation And AI Expansion Will Advance Lab Markets Despite Risks
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
07 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$16.00
17.6% undervalued
intrinsic discount
16 Aug
US$13.18
Loading
1Y
48.8%
7D
7.2%
Author's Valuation
US$16.0
17.6% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$16.0
17.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-3b
539m
2019
2021
2023
2025
2027
2028
Revenue US$203.2m
Earnings US$28.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
-4.84%
Life Sciences revenue growth rate
0.33%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
8.30%
Calculation
US$28.81m
Earnings '28
x
47.30x
PE Ratio '28
=
US$1.36b
Market Cap '28
US$1.36b
Market Cap '28
/
67.24m
No. shares '28
=
US$20.27
Share Price '28
US$20.27
Share Price '28
Discounted to 2025 @ 8.33% p.a.
=
US$15.94
Fair Value '25